The Global Protein Chip Market size is expected to reach $1,292. 55 million by 2027, rising at a market growth of 9. 11% CAGR during the forecast period. Protein chip refers to the miniaturized & parallel assay systems, which consists of less quantities of purified proteins in a high-density format.
New York, Dec. 27, 2021 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report "Global Protein Chip Market By End User, By Technology, By Application, By Regional Outlook, Industry Analysis Report and Forecast, 2021 – 2027" – https://www.reportlinker.com/p06193318/?utm_source=GNW
Protein chip is also called protein microarrays. It enables the simultaneous determination of a wide range of analytes from less quantity of samples under a single experiment. In addition, this protein chip comprises a support surface like bead, a glass slide, nitrocellulose membrane, or microtiter plate, on which a range of capture proteins is bound. Moreover, probe molecules that are generally labeled with a fluorescent dye are included in the array.
Further, Protein Chip is economical, automated, rapid, and more sensitive, using lesser number of samples and reagents. These protein microarrays have high-throughput technology behind them, which is comparatively simple to develop as it is based on technology made for DNA microarrays that have been broadly utilized microarrays. Additionally, this technology is utilized to monitor interactions & activities of proteins and to specify their function on a large scale.
COVID-19 Impact Analysis
The outbreak of the COVID-19 pandemic has positively impacted the protein chip market. It is because there is a high demand for protein chips from diagnostics laboratories. People infected with COVID-19 need to undergo several tests to find out the body’s vitals. The protein chip assists in the identification of proteins and the way the virus infects them, by offering them complete body check-ups.
During the initial phase of the pandemic, several governments have invested a lot in the R&D activities to study its effects and develop some treatments as well as the vaccines. During the research phase, protein chips have offered great support to the scientist and research labs in understanding the impact of the virus on the human body and developing a way to minimize these effects and treat patients.
Marketing Growth Factors:
Growing cases of chronic diseases, particularly cancer
Chronic disease is the term used for a group of diseases including cardiovascular diseases, cancer, diabetes and others. There is a rise in the number of chronic diseases among the population across the globe. It is caused majorly due to the sedentary lifestyle, unhealthy diet, and consumption of tobacco. According to WHO, Cancer is one of the top reasons behind death across the world that is approximately 10 million deaths in 2020. Among the total number of deaths due to cancer, approx. 70% of deaths were reported in low- and middle-income countries.
High Investment in R&D activities
There are many biotech companies which are increasing their investment in R&D activities to develop and improve different medications, procedures, and medical tools. In addition, the increase in research activities is estimated to surge the demand for protein chips in the market as they are highly utilized in various procedures. Protein chips are majorly utilized in determining protein activities and functionalities. In addition, the significant utility of these chips in the identification of post-translational modifications (PTMs) is fueling the protein chips in proteomics research. Thus, the demand for protein chips would augment in the coming years.
Marketing Restraining Factor:
Complications associated with protein chip
There are many complexities attached to the usage of protein chips by researchers. The challenge of producing proteins in a high-throughput way would hinder the growth of the protein chip market during the forecast period. It is a scientific approach for experiments that include the automation of screening the activities against the biological targets. However, the quality of protein used in these experiments can impact the results and thus, restrict its usage among the customers.
On the basis of technology, the protein chip market is segmented into analytical microarrays, functional protein microarrays, and reverse-phase protein microarrays. The analytical microarray segment dominated the protein chip market in 2020 by obtaining the highest revenue share and is estimated to showcase the similar kind of trend even during the forecast period.
By application, the protein chip market is divided into diagnostics, proteomics, and antibody characterization. Among these, the antibody characterization segment acquired a significant revenue share of the market in 2020 and is anticipated to maintain this trend over the forecast period. It is owing to the benefits of these chips, which include more sensitivity/specificity, decrease in biological sample volume, and huge data generation.
Based on end-user, the protein chip market is classified into hospitals & clinics, academic & research institutes, diagnostic laboratories, and pharmaceutical & biotechnological companies. The academic & research institutes segment is projected to garner the maximum market share over the forecast period.
By region, the protein chip market is analyzed across North America, Europe, Asia Pacific, and LAMEA. In 2020, North America emerged as the leading region in the protein chip market due to the well-established and reputed protein chip laboratories and research centers across the region.
The major strategies followed by the market participants are Product Launches. Based on the Analysis presented in the Cardinal matrix; Thermo Fisher Scientific, Danaher Corporation, Bio-Rad Laboratories are the forerunners in the Protein Chip Market. Companies such as Merck Group, Illumina Inc., Perkin Elmer, and Agilent Technologies are some of the key innovators in Protein Chip Market.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., PerkinElmer, Inc., Thermo Fisher Scientific, Inc., RayBiotech Life, Inc., Quotient limited, Danaher Corporation, Arrayit Corporation, Merck Group, and Illumina, Inc.
Recent Strategies Deployed in Protein Chip Market
Partnerships, Collaborations and Agreements:
Jun-2021: Thermo Fisher Scientific signed an agreement with Advanced Electrophoresis Solutions Ltd (AES), specialists in protein imaging technologies. This agreement aimed to integrate important protein separation techniques with mass spectrometry (MS) to improve therapeutic protein development via streamlined characterization.
Jun-2021: Bio-Rad Laboratories came into a partnership with Seegene, a global leader in multiplex molecular diagnostics. In this partnership, Seegene would offer diagnostic tests for usage on Bio-Rad’s CFX96 Dx Real-Time PCR System for U.S. markets pending clinical development & clearance from The U.S. Food & Drug Administration (FDA).
Apr-2021: Illumina came into a partnership with Kartos Therapeutics, a clinical-stage biopharmaceutical company. This partnership aimed to co-develop a TP53 companion diagnostic (CDx) based on the content of Illumina’s comprehensive genomic profiling assay, TruSight Oncology 500 (TSO 500).
Mar-2021: Thermo Fisher Scientific entered into an agreement with Protein Metrics, a developer of world-class software tools for protein characterization. This agreement aimed to offer improved mass spectrometry data processing and analysis capabilities to fuel innovation across the whole spectrum of biopharmaceutical & proteomics applications, ranging from research and development to quality control.
Mar-2021: Merck formed a partnership with the Faculty of Mathematics and Natural Sciences, Universitas Indonesia (FMIPA-UI). This partnership aimed to set up the first Collaboration Laboratory between the company and the university to improve life science research & innovation development in Indonesia.
Jan-2021: Illumina joined hands with Helix, a population genomics company. This collaboration aimed to supervise the emergence and prevalence of novel strains of SARS-CoV-2 with support from the CDC. The integration of Illumina’s sequencing technology & expertise with Helix’s national COVID-19 testing footprint would substantially expand the country’s prevailing surveillance efforts to identify and characterize emerging variants of SARS-CoV-2.
Dec-2020: Agilent Technologies signed an agreement with SomaLogic, a protein biomarker discovery and clinical diagnostics company. This agreement aimed to supply personalized high-fidelity oligo microarrays for usage in the nucleic acid detection step under SomaLogic’s novel SOMAscan assay, a protein measurement platform with applications over basic & clinical research, diagnostics, and pharmaceutical discovery and development.
May-2020: Thermo Fisher Scientific came into an agreement with MSAID, a software company transforming proteomics. This agreement aimed to make and commercialize deep learning tools for proteomics, which would develop MSAID’s Prosit-derived framework widely accessible to proteomics laboratories.
May-2020: Quotient joined hands with hVIVO, part of Open Orphan. Under this collaboration, MosaiQ by Quotient system and MosaiQ COVID-19 Antibody Microarray would be utilized by hVIVO to screen for SARS-CoV-2 antibodies (COVID-19). This collaboration would also be uniquely positioned to leverage Quotient combined expertise and assist in fulfilling the large requirement for antibody testing in the U.K. and beyond.
Product Launches and Product Expansions:
Jul-2021: Quotient released Multimodal, Multiplex Microarray for Transfusion Diagnostic testing with a multiplex, multimodal platform. This platform is monitoring the development of the system for additional diagnostic applications.
Mar-2020: Agilent Technologies launched three new microarrays to fulfill the requirements of cytogenetic laboratories conducting both prenatal and postnatal research. This latest Agilent GenetiSure Cyto microarrays consist of updated, clinically relevant content from respected databases. The probes on the Cyto microarrays offer high-resolution detection of copy number variations, and copy-neutral loss of heterozygosity related to developmental delay, intellectual disability, neuropsychiatric disorders, congenital anomalies, or unexplained dysmorphic features in constitutional DNA samples.
Acquisitions and Mergers:
Nov-2021: Thermo Fisher Scientific took over PharmaFluidics, the developer of the ?PAC range of micro-chip-based chromatography columns. The µPAC portfolio of columns would improve liquid chromatography (LC) performance in proteomics, biomarker, and drug research and development applications, assisting biotechnology and pharmaceutical enterprises to unleash new insights and advance scientific discovery.
Aug-2021: Illumina took over GRAIL, a healthcare company focused on life-saving early detection of multiple cancers. This acquisition aimed to increase access and adoption of the life-saving test across the world.
Aug-2021: Danaher Corporation acquired Aldevron, a biotechnology company. This acquisition aimed to expand Danaher Corporation’s capabilities into the crucial field of genomic medicine and also assist companies to support their customers and their critical mission to bring more life-saving therapies and vaccines to market quickly.
Jun-2020: Illumina acquired BlueBee, a cloud-based software company. This acquisition aimed to improve the company’s capabilities to evaluate and interpret the data generated by its sequencing systems.
Apr-2020: Bio-Rad Laboratories took over Celsee, a global leader of life science research and clinical diagnostic products. This acquisition aimed to expand Bio-Rad’s reach into the swiftly expanding world of precision medicine and single-cell analysis, which would provide better insight into diagnosis, disease, and treatment.
Sep-2021: Illumina expanded its geographical footprints in Latin America by making Illumina Colombia and Illumina México Productos de Biotecnología. This expansion aimed to boost the level of support for the company’s local customers and partners.
Mar-2021: Merck expanded its geographical footprint by establishing a production unit at its Life Science Center in Molsheim, France. Through the € 25 million investment, the company would boost its European expansion for this key technology that is utilized for the production of Covid-19 vaccines and other lifesaving therapies.
Scope of the Study
Market Segments covered in the Report:
By End User
• Pharmaceuticals and Biotechnology Sector
• Academic & Research Institutes
• Diagnostic Laboratories and
• Hospitals and Clinics
• Analytical Microarrays
• Functional Protein Microarrays and
• Reverse Phase Protein Microarrays
• Proteomics and
• Antibody Characterization
• North America
o Rest of North America
o Rest of Europe
• Asia Pacific
o South Korea
o Rest of Asia Pacific
o Saudi Arabia
o South Africa
o Rest of LAMEA
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• PerkinElmer, Inc.
• Thermo Fisher Scientific, Inc.
• RayBiotech Life, Inc.
• Quotient limited
• Danaher Corporation
• Arrayit Corporation
• Merck Group
• Illumina, Inc.
• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free
Read the full report: https://www.reportlinker.com/p06193318/?utm_source=GNW
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.
Every investor in NIO Inc. ( NYSE:NIO ) should be aware of the most powerful shareholder groups. Generally speaking, as…
Sorrento Therapeutics Inc. announced Monday a contract for the sale and distribution of up to 10 million its Covistix rapid COVID-19 virus detection tests in Mexico. That follows a previously announced deal for up to 5 million Covistix tests in Mexico, bringing the total number of tests to 15 million. The biopharmaceutical company said independent clinical testing of Covistix by a Mexico-based national institute showed a "very high sensitivity" of around 90% in an "all-comers" population, includ
As we get ready to turn the page on 2021, I can't help but note how we've witnessed a pretty substantial market bifurcation in stocks over the past couple of quarters. Below are four stocks that I believe are likely to find their way into my portfolio in 2022. A year ago, I was completely against electric vehicle (EV) manufacturer Nio (NYSE: NIO).
Since the Great Recession officially ended in 2009, growth stocks have been the driving force on Wall Street. Low lending rates, massive government spending, and the Federal Reserve providing an abundant pool of cheap capital have incentivized businesses to hire, innovate, and acquire other companies. The chickens are now coming home to roost in terms of runaway inflation, and though the Fed has indicated rate hikes are coming to combat high prices, effects won't be felt right away.
It's been a dreadful year for Citigroup (NYSE: C) in terms of stock price performance, with shares of the megabank down about 1% this year. The KBW Nasdaq Bank Index, which tracks large bank stocks, is up nearly 35% this year, showing just how much Citigroup has lagged the broader sector. Trading at beaten-down levels, can Citigroup turn it around in 2022?
ClearBridge Investments, an investment management firm, published its “Small Cap Value Strategy” third quarter 2021 investor letter – a copy of which can be downloaded here. The ClearBridge Small Cap Value Strategy outperformed the Russell 2000 Value Index, the Strategy’s benchmark, during the third quarter of 2021. You can take a look at the fund’s […]
The dividends for such stocks are pretty much their only attraction. On the other hand, you can find dividend stocks that are anything but boring and stodgy. Here are three dividend stocks that soared more than 50% in 2021 and are still great buys.
Abbott Laboratories (NYSE: ABT) shares have gained around 26% in 2021. Despite the big payout bumps, Abbott only needed around 33% of the free cash flow its operations generated over the past year to make dividend payments. Despite pandemic pressure, medical-device segment sales during the first nine months of 2021 rose 24.5% year over year to $10.6 billion.
Web 3.0 is widely considered to be the next frontier of internet technology, making the metaverse a golden macrotrend for retail investors. The metaverse refers to an easily scalable real-time virtual reality or mixed reality world, comprising several interoperable, immersive, and interactive 3D environments. The metaverse is also expected to maintain all relevant information about payments, identity, and history across user sessions.
This mix of industrial and renewable energy companies could be a great way to generate passive income next year.
Shares of Microbot Medical Inc. rocketed 67.3% toward a nine-month high on heavy volume in premarket trading Monday, after the pre-clinical medical device company announced an agreement with Stryker Corp. to develop the first dedicated robotic procedural kits for use in certain neurovascular procedures. Trading volume ballooned to 9.6 million shares, compared with the full-day average of about 49,000 shares. The stock was the biggest gainer and most actively traded ahead of the open. As part of
Genetic testing company Invitae (NYSE: NVTA) has seen its shares tumble from their highs despite aggressively ramping up its test volumes this year. Investors could buy the dip on Invitae, but they shouldn't ignore a major hang-up on its business model. Invitae generates revenue by administering genetic tests while steadily also building a genome information database over time.
It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks…
If you have $100 at the ready not needed for bills or emergencies and a brokerage that allows fractional share purchases, you have enough to buy into the following pair of no-brainer stocks right now. Palantir Technologies (NYSE: PLTR) is the Liam Neeson of data analytics stocks: It has a very particular set of skills that were acquired over a very long career. The U.S. military is also a prime customer, using Palantir's technology to coordinate millions of troops around the world.
Stocks rose ahead of the traditional Santa Claus rally. Tesla is still rising. AMD leads stocks flashing buy signals.
There's no denying that 2021 has been a rough year for many biotech stocks. The shares of quite a few big and small biotech companies alike are set to finish the year in negative territory. Here's why they chose Axsome Therapeutics (NASDAQ: AXSM), Novartis (NYSE: NVS), and Vertex Pharmaceuticals (NASDAQ: VRTX).
Naren Gupta, a venture capitalist who co-founded Nexus Venture Partners to help plant Indian SaaS startups on the world map, died on Saturday. Gupta, who moved to the U.S. to pursue higher education in late 1960s, co-founded Integrated Systems, a software firm that was ultimately sold to Intel. After leaving the firm, he began to explore investment opportunities.
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Typically, we'll want to…
One analyst wrestles with what the videogame retailer is versus what it could be, and comes away with a $23 price target.
Banks are healthy, but their catalysts for growth are murky. These half-dozen stocks rise above the pack, says one strategist.